Vial sizes vary by vendor. Smaller bottles are usually 3 mL; larger bottles are often 10 mL. Match the label on the vial you actually bought, then use the calculator below if you need to adjust.
Overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.
Preparation
Recon: 10 mg vial + 2 mL BAC (5 mg/mL).
Protocol
| Period | Dose | Units (@ 5mg/mL) | Frequency |
|---|---|---|---|
| Weeks 1-4 | 2.5 mg | 50 u | 1x/week |
| Weeks 5-8 | 5 mg | 100 u | 1x/week |
| Weeks 9-12 | 7.5 mg | 150 u | 1x/week |
| Weeks 13-16 | 10 mg | 200 u | 1x/week |
| Weeks 17-20 | 12.5 mg | 250 u | 1x/week |
| Weeks 21-24 | 15 mg | 300 u | 1x/week |
Cycle
12 weeks on, 4 weeks off.
Research coverage
Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on Tirzepatide Protocol.
- How Structural Design Defines Next-Generation GLP-1 Analogs Sep 15, 2026
A structural overview of how DPP-4 resistance, lipidation, signaling bias, and multi-receptor agonism produce progressively more sophisticated incretin therapies.
- Tirzepatide and Atrial Fibrillation: Meta-analysis Sep 14, 2026
A 10-trial Bayesian meta-analysis found tirzepatide was not linked to atrial fibrillation, while raising a cautious flag on broader arrhythmia outcomes.
- GLP-1 Agonists for MASH Fibrosis: an Overview Sep 8, 2026
A Cell Reports Medicine review surveys incretin-based therapies for MASH fibrosis — from FDA-approved semaglutide to emerging dual and triple GLP-1 agonists.